CELC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Celcuity Inc. (CELC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite short-term insider selling and a lack of immediate trading signals, the stock has strong long-term potential driven by positive analyst ratings, upcoming FDA priority review, and a promising drug pipeline. The technical indicators and options data also support a bullish sentiment.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 72.671, and moving averages are converging, suggesting a potential breakout. The stock is trading near its resistance level of 110.176, with support at 102.826.
Wells Fargo's Overweight rating with a $126 price target, citing strong market opportunity for gedatolisib.
Perceptive Advisors increased its stake, showing institutional confidence.
FDA Priority Review for the company's new drug application.
Insider selling has increased by 657.10% over the last month.
No recent congress trading data to confirm political interest.
Revenue remains at $0, indicating the company is still in a pre-revenue phase.
In Q3 2025, net income improved by 47.03% YoY to -$43.8M, and EPS increased by 31.43% YoY to -0.92. While the company remains unprofitable, these metrics show improving financial health.
Wells Fargo initiated coverage with an Overweight rating and a $126 price target, citing a largely de-risked drug pipeline and significant market opportunities in breast and prostate cancer.
